Drugs / SD-QIV
SD-QIV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02936180 Comparator | Oct 2016 → Jul 2018 | rheumatoid arthritis | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SD-QIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02936180 ↗ |
| Known as | FLUZONE Standard Dose Quadrivalent Inactivated Influenza Vaccine | “Patients will receive one dose of FLUZONE® Standard Dose Quadrivalent Inactivated Influenza Vaccine (SD-QIV)” NCT02936180 ↗ |
| Modality | Vaccine | “standard-dose quadrivalent influenza vaccine (SD-QIV)” NCT02936180 ↗ |